1. Scrip
  2. >>Business

Merck & Co. CEO Davis Debuts With A Leaner Organization And Money To Spend

 
• By Jessica Merrill

Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.

Deals Sign
Merck's new CEO outlined his business development strategy • Source: Alamy

Merck & Co., Inc..'s new CEO Robert Davis made his public debut as the company's leader during its second quarter sales and earnings call on 29 July. The leadership transition represents a new start for the company in multiple ways, as this is also the first quarter for Merck as a substantially leaner organization, having spun out its established products, biosimilars and women's health portfolio under the Organon moniker.

"I know it's not about promising. It's about performing. Actions speak louder than words," Davis said, opening the call with a vow to accelerate the delivery of new innovations to the market

More from Earnings

More from Business

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.